Pelvic organ prolapse, better known as POP, is a relatively common condition among post-menopausal women, especially those who’ve had multiple children. For a time, surgical mesh devices were marketed as the most effective treatment for POP, offering patients a less invasive procedure and a comparatively shorter recovery period. In a recent study highlighted last week at the annual conference of the Society of gynecologist Surgeons, a team of researchers found that rates of patient satisfaction and healing were the same whether a patient was treated using vaginal mesh or using tissue from her own body. More alarmingly, women who were implanted with synthetic mesh products were prone to suffering a host of severe transvaginal mesh complications, visit http://vaginalmeshlawsuit-lawyer.co to read more.
This safety concern mirrors that of the FDA, after the agency concluded that transvaginal placement of surgical mesh for the repair of POP and stress urinary incontinence (SUI) has been associated with a higher incidence of adverse events. Following a comprehensive review of clinical trials spanning from 1996 to 2011, the federal agency determined that mesh repairs of POP may not improve the recipient’s quality of life when compared to non-mesh treatment.
The FDA alerted consumers in a subsequent safety communication that serious complications were “not rare,” giving validation to the thousands of suffering mesh recipients across the nation. One of the most common complications reported by patients is vaginal mesh erosion, also referred to as extrusion – where the outer edges of the mesh slice through the surrounding tissue, often causing chronic infections and organ damage.
1 in 10 patients suffer vaginal mesh erosion, study says
Further research published in the May 15 edition of the Journal of the American Medical Association (JAMA) revealed that one in every ten patients experience transvaginal mesh complications – most notably, mesh erosion – and the majority also complain of urinary incontinence after the procedure. According to the study, which included 215 patients over the course of seven years, recipients of vaginal mesh had a 10.5 percent likelihood of mesh erosion.
The FDA has indicated that the risks of surgical mesh devices may outweigh any benefits when it comes to the treatment of POP, and in 2012, the agency asked mesh manufacturers to conduct additional tests to more accurately evaluate the safety of their products.
At present, several major manufacturers of mesh devices are facing thousands of complaints, which have been coordinated as multidistrict litigations (MDL). Among the defendants are American Medical Systems (AMS), Ethicon, C.R. Bard, Boston Scientific, Cotoplast and Mentor Corporation. All qualifying cases that allege similar injuries and side effects have been removed to the U.S. District Court for the Southern District of West Virginia for pre-trial proceedings.
Allegations of life-threatening injuries in transvaginal mesh lawsuits
Women who have taken legal action after sustaining mesh complications are seeking monetary damages to help cover costs of medical expenses, loss of wages, pain, suffering, and other losses.
Some of the more frequently alleged transvaginal mesh complications include:
- Vaginal mesh erosion
- Organ perforation and damage
- Persistent infections
- Chronic pain in the abdomen and pelvic region
- Recurrent urinary tract infections
- Recurrence of POP or SUI
- Bleeding and complications caused by mesh extrusion
- Need for revision surgery
Ava Lawson is a writer and editor for Injury Lawyer News with experience in medico legal reporting.